Innovent thyroid eye therapy hits phase III goal, spurs China NDA : vimarsana.com

In a crowded thyroid eye disease (TED) space, Innovent Biologics Inc. reported positive late-stage findings for its TED therapy, IBI-311, spurring the Suzhou, China-based biopharma to file for regulatory approval in China.

Related Keywords

Suzhou , Jiangsu , China , , Innovent Biologics Inc , Innovent Biologics , Innovent Biologics Inc , Phase Iii , Thyroid Eye Disease , Ted , Ibi 311 , Ind , Restore 1 , Igf 1r , Autoimmune Disease , Eye Diseases , Mazdutide , Bioworld , Bioworld Asia , Ocular , Nmpa , Asia Pacific ,